Yahoo
NasdaqGM - Nasdaq Real Time Price USD

biote Corp. (BTMD)

1.0300 -0.0100 (-0.96%)
As of 9:36:15 AM EST. Market Open.
BTMD Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for BTMD
  • Previous Close 1.0400
  • Open 1.0500
  • Bid 1.6200 x 200
  • Ask 2.9000 x 200
  • Day's Range 1.0200 - 1.0500
  • 52 Week Range 0.9900 - 2.9000
  • Volume 11,042
  • Avg. Volume 199,509
  • Market Cap (intraday) 34.916M
  • Beta (5Y Monthly) 1.74
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0700
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 2.61
  • Zacks Rating Bearish

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.

www.biote.com

223

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BTMD
60.38%
S&P 500 (^GSPC)
8.42%

1-Year Return

BTMD
63.73%
S&P 500 (^GSPC)
10.44%

3-Year Return

BTMD
81.44%
S&P 500 (^GSPC)
70.00%

5-Year Return

BTMD
89.50%
S&P 500 (^GSPC)
58.00%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 43.33M
Earnings 407k
Profit Margin 0.94%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
10M
20M
30M
40M
-10.0%
-5.0%
0.0%
5.0%

Analyst Insights

View More

Analyst Price Targets

1.50
2.61 Average
1.0300 Current
4.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/10/2026
Analyst B. Riley Securities
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 2 -> 1.5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.19%

  • Return on Assets (ttm)

    13.70%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    183.53M

  • Net Income Avi to Common (ttm)

    5.86M

  • Diluted EPS (ttm)

    -0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.17M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.99M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: